Overview

Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects

Status:
Completed
Trial end date:
2017-09-06
Target enrollment:
Participant gender:
Summary
The purpose of this Phase I, single-dose, open-label trial is to evaluate the pharmacokinetics and safety of ivosidenib (AG-120) in healthy, adult male Japanese and Caucasian subjects. The study plans to evaluate 3 cohorts of a single oral dose of ivosidenib (AG-120) in Japanese and Caucasian subjects. Pharmacokinetic sampling will take place serially through-out the duration of subject participation.
Phase:
Phase 1
Details
Lead Sponsor:
Agios Pharmaceuticals, Inc.
Treatments:
Ivosidenib